🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Zai Lab's CEO Du Ying sells shares worth over $93k

Published 04/03/2024, 09:45 PM

Zai Lab Ltd's (NASDAQ:ZLAB) Chairperson and CEO, Du Ying, has recently engaged in significant transactions involving the company's stock, according to a new filing with the Securities and Exchange Commission. On April 2, 2024, Du Ying sold a total of 5,787 American Depositary Shares (ADS) at an average price of $16.151, netting over $93,000.

These sales occurred right after Du Ying acquired 14,200 ADSs through the vesting of Restricted Share Units (RSUs) at a set price of $16.72 per share, amounting to a total transaction value of $237,424. It's noted that some of the shares sold were specifically to cover tax liabilities associated with the vesting of these RSUs.

Zai Lab, a pharmaceutical company based in Shanghai, is represented on the stock market by its ADSs, with each ADS equating to ten ordinary shares of the company. The RSUs, which represent a contingent right to receive ADSs, vest in equal annual installments over five years, with the vested shares delivered in the form of ADSs to the reporting person following vesting.

The recent transactions by the CEO are part of the normal course of employee compensation and stock ownership management. Investors often monitor such insider transactions for insights into executive confidence and company performance. As of the latest transactions, Du Ying's direct ownership in Zai Lab stands at 1,107,972 ADSs.

These filings provide transparency into the actions of company executives and are a routine part of corporate governance and compliance.

InvestingPro Insights

Zai Lab Ltd (NASDAQ:ZLAB) has been navigating challenging market conditions, as reflected in the company's recent financial metrics and stock performance. According to InvestingPro data, Zai Lab holds a market capitalization of approximately $1.58 billion USD, with a notable revenue growth of 24.03% over the last twelve months as of Q4 2023. Despite this growth, the company's gross profit margin remains negative at -35.6%, indicating struggles in maintaining profitability.

InvestingPro Tips suggest that while analysts anticipate sales growth in the current year, they do not expect Zai Lab to be profitable within the same timeframe. Furthermore, the stock has experienced a significant downturn, with a 1-month price total return of -22.14% and a 3-month price total return of -40.2%. This could be reflective of the broader market sentiment and specific challenges faced by the company, including weak gross profit margins and downward earnings revisions by analysts for the upcoming period.

For those closely following Zai Lab's financial health and stock performance, InvestingPro offers additional insights. There are 13 more InvestingPro Tips available for Zai Lab, providing a comprehensive analysis that could be valuable for investors. To explore these tips and gain a deeper understanding of Zai Lab's financial landscape, visit https://www.investing.com/pro/ZLAB and use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.